Kim Stratton serves as Chief Executive Officer at CENTOGENE, the essential life science partner for data-driven answers in rare and neurodegenerative diseases. Kim has more than 30 years’ global commercial expertise in the biopharmaceutical space, with significant experience across multiple geographies, including Europe, the U.S., APAC, and LATAM. Most recently, Kim served as CEO of Orphazyme, a biopharmaceutical company dedicated to developing treatments for patients living with rare diseases. Prior to this role, she worked at Shire Pharmaceuticals, where she served as Head of International Commercial for Shire’s Specialty and Rare Disease portfolio. Before Shire, Kim spent nearly 15 years at Novartis in a number of senior management roles, including Global Head Corporate Public Affairs, Global Business Franchise Head, and Country Management. Kim is on the Board of Recordati S.p.A and Novozymes A/S.